← FDA DRUG APPROVALS

FDA ANDA · ANDA064200

CEFOTAXIME

Sponsor: FRESENIUS KABI USA

APPLICATION
ANDA064200
TYPE
ANDA
ORIGINAL APPROVAL
2000-03-24
LATEST ACTION
2008-04-30
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

CEFOTAXIMEDiscontinued
CEFOTAXIME SODIUM EQ 1GM BASE/VIAL · INJECTABLE · INJECTION
CEFOTAXIMEDiscontinued
CEFOTAXIME SODIUM EQ 2GM BASE/VIAL · INJECTABLE · INJECTION
CEFOTAXIMEDiscontinued
CEFOTAXIME SODIUM EQ 500MG BASE/VIAL · INJECTABLE · INJECTION

Approval history

2008-04-30Labeling · Supplement 11AP
2005-09-01Labeling · Supplement 10AP
2004-03-17Labeling · Supplement 7AP
2004-03-17Labeling · Supplement 8AP
2002-08-13Manufacturing (CMC) · Supplement 6AP
2002-03-28Manufacturing (CMC) · Supplement 4AP
2002-01-04Manufacturing (CMC) · Supplement 3AP
2001-06-28Manufacturing (CMC) · Supplement 1AP
2001-06-28Manufacturing (CMC) · Supplement 2AP
2000-03-24OriginalReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →